AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04330248
Drug: Carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive an oral dose of carbamazepine tablets from Day 15 to 35 in Period 2.
Trial: NCT02790177
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02325986
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
Trial: NCT00843882
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04234113
Drug: Nanrilkefusp alfa
RxNorm normalized name: Nanrilkefusp alfa
DrugBank: Nanrilkefusp alfa (DB17480)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A fusion protein which consists of the N-terminal sushi domain of human IL-15 receptor α covalently coupled via a linker of 20 amino acids to human IL-15
Trial: NCT04234113
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A humanized IgG4 monoclonal antibody with high specificity of binding to the PD-1 receptor
Trial: NCT00640978
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg by mouth daily for 28 Days
Trial: NCT03778047
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT01903486
Drug: Apo-Prednisone Cordorol, Detasone - Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
Trial: NCT03003962
Drug: Paclitaxel + carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy Agents
Trial: NCT00163384
Drug: Ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04485052
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Demethylation drugs
Trial: NCT04485052
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Demethylation drugs
Trial: NCT02006706
Drug: rituximab [MabThera/Rituxan]
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000 mg iv Days 1 and 15
Trial: NCT03003962
Drug: Gemcitabine + cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy Agents
Trial: NCT03003962
Drug: Gemcitabine + carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy Agents
Trial: NCT03003962
Drug: Pemetrexed + cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy Agent
Trial: NCT03003962
Drug: Pemetrexed + carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy Agent
Trial: NCT02006706
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
Trial: NCT02816853
Drug: Domperidone
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 10 mg or 20 mg tablets will be administered.
Trial: NCT00555256
Drug: sunitinib and rapamycin (Drug will be held)
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Any toxicity causing a total of 14 days delay of therapy will be considered dose limiting.
Trial: NCT01788046
Drug: Etelcalcetide
RxNorm normalized name: Etelcalcetide
DrugBank: Etelcalcetide (DB12865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
Trial: NCT02816853
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg tablet will be administered.
Trial: NCT01924871
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane
Trial: NCT04110028
Drug: Nicotinamide riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide riboside in different doses
Trial: NCT03676192
Drug: CT-P16
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/kg IV of CT-P16 every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
Trial: NCT03676192
Drug: Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg/kg IV of Avastin every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
Trial: NCT00431262
Drug: antabuse (disulfiram)
RxNorm normalized name: disulfiram Oral Tablet [Antabuse]
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04509973
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ATC code: H02AB02
Trial: NCT03336281
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.
Trial: NCT00570765
Drug: Obeticholic Acid (OCA)
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.
Trial: NCT04234607
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a multi-target receptor tyrosine kinase inhibitor
Trial: NCT01957735
Drug: BP31510 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01957735
Drug: BP31510 in combination with chemotherapy
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04234607
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide is a cell cycle-specific antitumor drug
Trial: NCT04234607
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is cell cycle nonspecific antitumor drug
Trial: NCT02254148
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single dose of midazolam given as oral solution (day 1 of visits 2 and 3)
Trial: NCT02254148
Drug: digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of digoxin given as tablets (day 3 of visits 2 and 3)
Trial: NCT02254148
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of warfarin given as tablets (day 1 of visits 2 and 3)
Trial: NCT02254148
Drug: omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of omeprazole given as tablet (day 1 of visits 2 and 3)
Trial: NCT02824315
Drug: AL-335
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.
Trial: NCT02824315
Drug: Odalasvir (ODV)
RxNorm normalized name: ODV
DrugBank: Odalasvir (DB13041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.
Trial: NCT02824315
Drug: Simeprevir (SMV)
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
Trial: NCT02254148
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses of BI 187004 given as tablets (day 7-12 of visit 2 and day 1-6 of visit 3)
Trial: NCT02254148
Drug: metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of metoprolol given as tablets (day 1 of visits 2 and 3)
Trial: NCT00885690
Drug: Sertindole
RxNorm normalized name: sertindole
DrugBank: Sertindole (DB06144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole 16-24 mg once daily
Trial: NCT00885690
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine 10-20 mg
Trial: NCT00045448
Drug: alvocidib
RxNorm normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03841773
Drug: TNX-102 SL
RxNorm normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
Trial: NCT04590963
Drug: Monalizumab
RxNorm normalized name: Monalizumab
DrugBank: Monalizumab (DB12824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusion of monalizumab as stated in arm description.
Trial: NCT00045448
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01508026
Drug: Nebivolol and Valsartan 1
RxNorm normalized name: valsartan and nebivolol
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration
Trial: NCT04238416
Drug: Branched chain amino acid
RxNorm normalized name: Branched Chain Amino Acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
Trial: NCT04238416
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral lactulose will be given to patients in both arms
Trial: NCT04590963
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive IV infusion of cetuximab as stated in arm description.
Trial: NCT02694822
Drug: Zalifrelimab
RxNorm normalized name: Zalifrelimab
DrugBank: Zalifrelimab (DB15632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An anti-CTLA-4 monoclonal antibody.
Trial: NCT01508026
Drug: Nebivolol and Valsartan 2
RxNorm normalized name: valsartan and nebivolol
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration
Trial: NCT02424617
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received erlotinib 150 mg for the 21-day cycle.
Trial: NCT02424617
Drug: Bemcentinib
RxNorm normalized name: Bemcentinib
DrugBank: Bemcentinib (DB12411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received bemcentinib 600 mg on Days 1 and 2 as loading dose and bemcentinib 200 mg as daily maintenance dose for the 21-day cycle.
Trial: NCT01508026
Drug: Nebivolol and Valsartan 3
RxNorm normalized name: valsartan and nebivolol
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration
Trial: NCT01508026
Drug: Nebivolol 1
RxNorm normalized name: nebivolol 10 MG
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration
Trial: NCT02424617
Drug: Bemcentinib
RxNorm normalized name: Bemcentinib
DrugBank: Bemcentinib (DB12411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received starting loading dose of bemcentinib 600 mg (200 mg on Days 1, 2 and 3) and bemcentinib 100 mg as daily maintenance dose for the 21-day cycle.~Depending on tolerability and DLT, the loading dose of bemcentinib was escalated to 800mg (400 mg on Days 1 and 2) and bemcentinib 100 mg as daily maintenance for the 21- day cycle and to 1200 mg daily (600 mg on Days 1 and 2, or 400 mg on Days 1, 2 and 3) and bemcentinib 200 mg as daily maintenance for the 21- day cycle).
Trial: NCT02424617
Drug: Bemcentinib
RxNorm normalized name: Bemcentinib
DrugBank: Bemcentinib (DB12411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received bemcentinib 400 mg on Days 1, 2 and 3 as loading dose and bemcentinib 200 mg as daily maintenance dose for the 21-day cycle.
Trial: NCT04515849
Drug: Cotadutide 100 micrograms
RxNorm normalized name: Cotadutide
DrugBank: Cotadutide (DB15194)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotadutide 100 micrograms administered subcutaneously
Trial: NCT04515849
Drug: Cotadutide 300 micrograms
RxNorm normalized name: Cotadutide
DrugBank: Cotadutide (DB15194)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotadutide 300 micrograms administered subcutaneously
Trial: NCT04515849
Drug: Cotadutide 600 micrograms
RxNorm normalized name: Cotadutide
DrugBank: Cotadutide (DB15194)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotadutide 600 micrograms administered subcutaneously
Trial: NCT04515849
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide 1.0 miligrams administered subcutaneously
Trial: NCT01508026
Drug: Nebivolol 2
RxNorm normalized name: nebivolol 20 MG
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration
Trial: NCT01508026
Drug: Valsartan 1
RxNorm normalized name: valsartan 16 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration
Trial: NCT01508026
Drug: Valsartan 2
RxNorm normalized name: valsartan 26 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration
Trial: NCT02802943
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients will receive imiquimod (Aldara®) as local adjuvant, applied topically at the side of vaccination 18h to 24h prior to the vaccination.
Trial: NCT00805909
Drug: NI-0401
RxNorm normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 daily infusions with escalating doses of NI-0401
Trial: NCT02601027
Drug: Bupivacaine infusion
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02601027
Drug: Acetominophen
RxNorm normalized name: acetominophen 500 MG / dextromethorphan HBr 15 MG / doxylamine succinate 6.25 MG / pseudoephedrine HCl 30 MG per 15 ML Oral Solution
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02601027
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02601027
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02601027
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03547973
Drug: Sacituzumab Govitecan-hziy
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously.
Trial: NCT03547973
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered per package insert
Trial: NCT03547973
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered per package insert
Trial: NCT03547973
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered per package insert
Trial: NCT03547973
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT03547973
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered per package insert
Trial: NCT03547973
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered per package insert
Trial: NCT03547973
Drug: Domvanalimab
RxNorm normalized name: Domvanalimab
DrugBank: Domvanalimab (DB18848)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT03547973
Drug: Enfortumab Vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT03010059
Drug: JNJ-64041575 (oral suspension formulation)
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.
Trial: NCT03010059
Drug: JNJ-64041575 (oral tablet formulation )
RxNorm normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.
Trial: NCT01722812
Drug: Cromoglicate
RxNorm normalized name: Cromoglicate
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice daily topical treatment for 14 days
Trial: NCT03453528
Drug: 68Ga-PSMA
RxNorm normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).
Trial: NCT03837821
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abemaciclib 200 mg oral, every 12 hours
Trial: NCT02722369
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT02722369
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT02722369
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT02722369
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintenance Agent
Trial: NCT00879099
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.
Trial: NCT00879099
Drug: timolol maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.